Immunotec Inc.

Immunotec Inc.

December 09, 2010 13:01 ET

Immunotec CEO to Retire at the End of the Year

VAUDREUIL-DORION, QUEBEC--(Marketwire - Dec. 9, 2010) - Immunotec Inc. (TSX VENTURE:IMM), a Canadian based company and a leader in the wellness industry (the "Company"), today announced that James A. Northrop and the Company have reached a mutual agreement that he will retire at the end of 2010.

"Jim has served as Immunotec's President and CEO for three years and we thank him for his diligent service in guiding the company during this period", said Bob Henry, Immunotec's Executive Chairman. Effective January 1st, Mr. Henry, will assume the additional role of CEO of Immunotec.

"I will work closely with Jim and the Executive Team to insure that the transition in leadership is executed smoothly", said Mr Henry. The Company remains committed with its leading distributors to insure that the current initiatives and programs, will be implemented to make Immunotec a first class network marketing company.

About Immunotec Inc.

Immunotec is a world class business opportunity supported by unique scientifically proven products that improve wellness. Headquartered with manufacturing facilities near Montreal, Canada, the Company also has distribution capacities to support its commercial activities in Canada and internationally to the United States, Europe, Mexico and The Caribbean.

The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at and on the Company's website at The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.


Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec's most recent Management's Discussion and Analysis, which can be found at Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

"The TSX Venture does not accept responsibility for the adequacy or accuracy of this release."

Contact Information

  • Patrick Montpetit
    VP and Chief Financial Officer